Page last updated: 2024-09-03

up 269-6 and angiotensin iii

up 269-6 has been researched along with angiotensin iii in 1 studies

Compound Research Comparison

Studies (up 269-6)	Trials (up 269-6)	Recent Studies (post-2010) (up 269-6)	Studies (angiotensin iii)	Trials (angiotensin iii)	Recent Studies (post-2010) (angiotensin iii)
15	4	0	628	4	53

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cazes, M; Cloarec, A; Provost, D; Versigny, A	1

Other Studies

1 other study(ies) available for up 269-6 and angiotensin iii

Article	Year
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. European journal of pharmacology, 1995, Sep-15, Volume: 284, Issue:1-2 Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents	1995

Article

Year

In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.

European journal of pharmacology, 1995, Sep-15, Volume: 284, Issue:1-2

Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents

1995